• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training

Major Drugs for treatment of COVID19

Pharmintel has compiled the list of top drugs which are in trial for the treatment of COVID19 considering the resent surges of treatment for COVID19 & to provide a one stop solution to all your data needs.

CompanyDrug NameGeneric NamePhaseType
Fujifilm Toyama Chemical Avigan Favipiravir Phase III RNA-dependent RNA polymerases (RdRps) Inhibitor
Abbivie Kaletra® (also marketed as Aluvia) lopinavir/ritonavir Phase Not Available HIV-1 protease inhibitor / Mechanism of Action
Sanofi & Regeneron Kevzara® sarilumab Phase 2/3 Fully-human interleukin-6 (IL-6) monoclonal antibody | IL-6 inhibitor
CytoDyn PRO 140 leronlimab  Phase 2 Humanised monoclonal antibody
Regeneron Pharmaceuticals REGN3048 / REGN3051 Not Available Preclinical Neutralising monoclonal antibodies
Gilead Sciences Remdesivir  GS-5734 Phase 3 Investigational Nucleoside Analogue RNA-dependent RNA polymerases (RdRps) Inhibitor
Roche Actemra® tocilizumab Phase 2 Interleukin-6 (IL-6) Receptor-Inhibiting Monoclonal Antibody
Roche Avastin bevacizumab Phase 2/3 VEGF inhibitor
HUmanigen lenzilumab lenzilumab Phase 3 Anti GM-CSF
EUSA Pharma Sylvant Not Available Observational IL-6 inhibitor
Mateon Therapeutics, Inc OT-101 OT-101 Preclinical TGF-Beta antisense drug
University of MInnesota chloroquine / hydroxychloroquine chloroquine / hydroxychloroquine Phase 2/3 ACE-2 inihibitor
Institut De Cardiologie De Montereal Colchicine Colchicine Phase 3 tubulin disruption
Southeast University AiRuiKA camrelizumab Phase 2 antiprogrammed cell death protein (PD-1) antibody
Synairgen, SNG001 Not Available Phase 2 IFN-beta-1a
Roivant Sciences gimsilumab gimsilumab Phase 1 Anti GM-CSF
VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China Mesenchymal stem cells Mesenchymal stem cells Phase 1/2 Tissue regeneration
University of MInnesota Losartan Losartan Phase 1 AT1R inihibitor
AscletisGanovo® (danoprevir) plus ritonavir; ASC09 and ritonavir; ASC09 and oseltamivir; ritonavir and oseltamivir; danoprevir Phase 4 HIV protease inhibitors
Apeiron Biologics APN01 Not Available Phase 1 Recombinant human angiotensin-converting enzyme 2 (rhACE2)
AIM ImmunoTech Ampligen®  rintatolimod Exploratory  Immune modulator indicated for severe chronic fatigue syndrome
Janssen Prezcobix darunavir / cobicistat Phase 3 HIV-1 protease inhibitor & CYP3A inhibitor
OncoImmune, Inc. CD24Fc Not Available Phase 3 IL-6 inhibitor
BioXyTran BXT-25 Not Available Exploratory Anti-necrosis drug
Sorrento and Celularity CYNK-001 Not Available Not Available Allogeneic placental-derived Natural Killer (NK) cell therapy
RedHill Opaganib (Yeliva®, ABC294640) / RHB-107 Not Available Exploratory sphingosine kinase-2 (SK2) selective inhibitor (oral)
Beroni Group Nanobody-based treatment Not Available Exploratory Modified nanobody
Tiziana Life Sciences & Novimmune TZLS-501 Not Available Exploratory a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb)
Biocryst Galidesivir BCX4430 Exploratory  Nucleoside RNA polymerase inhibitor designed to disrupt the viral replication process
Novartis Gilenya fingolimod Phase 2 sphingosine 1-phosphate receptor modulator
Relief Therapeutics & NeuroRx Aviptadil Not Available Phase 2 IL-6 inhibitor
JSC Pharmstandard Arbidol Umifenovir  Failed trial broad specturm anti-viral
Beijing Staidson Biopharma and InflaRx IFX-1 Not Available Phase 2 Humanised monoclonal antibody against factor C5a

Pharmintel has also prepared a customized dashboard which covers explicit information relevant to COVID19 on real time basis. Please email us at [email protected] your request if you require the dashboard sample for free.

Leave a Reply

Your email address will not be published.

+91 9643310025, 9643312749
© 2021 Pharmintel